Wilson HTM published yesterday.They have a 12 month price target...

Wilson HTM published yesterday.

They have a 12 month price target of about $1.61 (from memory)

They are assuming that BTA licences LANI for ROW and that a 15% royalty is shared by BTA and DS.

They are assigning a 75% probability to LANI getting FDA approval.

IN OTHER WORDS - THE WILSON HTM TEAM does not recognise that BTA now plans to manage stockpile sales itself, capturing the bulk of the spoils for BTA (and DS).

I think that this is SLOPPY RESEARCH.